Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025:1480:361-370.
doi: 10.1007/978-3-031-92033-2_23.

Iron Chelation Therapy

Maria Domenica Cappellini  1 , Natalia Scaramellini  2   3 , Simona Leoni  2   3 , Irene Motta  2   3
Affiliations
Review

Iron Chelation Therapy

Maria Domenica Cappellini et al. Adv Exp Med Biol. 2025.

Abstract

Iron overload is a serious complication associated with transfusion-dependent anemias and anemias characterized by ineffective erythropoiesis. Iron accumulation is toxic to many tissues, causing heart failure, cirrhosis, liver cancer, growth retardation, and multiple endocrine abnormalities.Chelation therapy aims to balance the rate of iron accumulation from blood transfusions by increasing iron excretion in urine and/or feces with chelators. Three iron chelators are currently available to treat patients: one administered parenterally called deferoxamine (or desferrioxamine) and two oral chelators, deferiprone and deferasirox. Careful dose adjustment is necessary to avoid excess chelation as iron levels fall.A key factor for successful iron chelation is to achieve regular adherence to treatment regimens throughout life: while the convenience and tolerability of individual chelators are important in achieving this goal, other factors such as psychological well-being and family and institutional support also impact adherence and outcomes.

Keywords: Deferasirox; Deferiprone; Deferoxamine; Iron overload; Transfusion-dependent anemias.

PubMed Disclaimer

References

    1. Anderson LJ, Holden S, Davis B, Prescott E, Charrier CC, Bunce NH et al (2001) Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J 22(23):2171–2179 - PubMed - DOI
    1. Balveer K, Pyar K, Wonke B (2000) Combined oral and parenteral iron chelation in beta thalassaemia major. Med J Malaysia 55(4):493–497 - PubMed
    1. Borgna-Pignatti C, Gamberini MR (2011) Complications of thalassemia major and their treatment. Expert Rev Hematol 4(3):353–366 - PubMed - DOI
    1. Borgna-Pignatti C, Cappellini MD, De Stefano P, Del Vecchio GC, Forni GL, Gamberini MR et al (2006) Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major. Blood 107(9):3733–3737 - PubMed - DOI
    1. Breuer W, Cabantchik ZI (2001) A fluorescence-based one-step assay for serum non-transferrin-bound iron. Anal Biochem 299(2):194–202 - PubMed - DOI

MeSH terms

LinkOut - more resources